This video illustrates the mechanism of HPV infections and how they can transform into cervical pre-cancer.
American Cancer Society. Global Cancer Facts & Figures. 2nd ed. Atlanta, GA: American Cancer Society; 2011. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf. Accessed November 22, 2013.
The American College of Obstetricians and Gynecologists. Cervical Cancer Screening Frequently Asked Questions. 2013.
Arbyn M, Anttila A, Jordan J, et al; for the International Agency for Research on Cancer. European Guidelines for Quality Assurance in Cervical Cancer Screening. 2nd ed. Belgium: European Communities; 2008. http://screening.iarc.fr/doc/ND7007117ENC_002.pdf. Accessed January 30, 2014.
Australian Government Department of Health. National Cervical Screening Program. Key statistics. http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/cervical-screening-1. Accessed March 31, 2015.
Barcelos AC, Michelin MA, Adad SJ, Murta EF. Atypical squamous cells of undetermined significance: Bethesda classification and association with Human Papillomavirus. Infect Dis Obstet Gynecol. Epub 2011 Jun 29.
Bergeron C, Ordi J, Schmidt D, et al. Conjunctive p16INK4a testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia. Am J Clin Pathol. 2010;133(3):395-406.
Canadian Cancer Society. Anatomy and physiology of the cervix. http://www.cancer.ca/en/cancer-information/cancer-type/cervical/anatomy-and-physiology/?region=on. Accessed December 5, 2013.
Cancer Research UK. Cervical cancer incidence statistics. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/cervix/incidence/. Accessed December 6, 2013.
Carozzi F, Gillio-Tos A, Confortini M, et al. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 2013;14(2):168-176.
Castle PE, Shaber R, LaMere BJ, et al. Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California. Cancer Epidemiol Biomarkers Prev. 2011;20(5):946-953.
CINtec® p16 Histology [package insert]. Ventana Medical Systems; 2012.
Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008;26 (Suppl 10):K29-K41.
Datamonitor Healthcare. Cervical cancer epidemiology. 2012. http://www.datamonitorhealthcare.com. Accessed August 16, 2013.
Farlex Online Medical Dictionary. Low-grade squamous intraepithelial lesion. http://medical-dictionary.thefreedictionary.com/low-grade+squamous+intraepithelial+lesion. Accessed January 8, 2014.
Gakidou E, Nordhagen S, Obermeyer Z. Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med. 2008;5(6)e132:863-868.
GLOBOCAN 2012. GLOBOCAN Cancer Fact Sheets: Cervical Cancer. Cervical cancer incidence, mortality, and prevalence worldwide in 2012 summary. International Agency for Research on Cancer website. http://globocan.iarc.fr/old/FactSheets/cancers/cervix-new.asp. Accessed March 30, 2015.
Ikenberg H, Bergeron C, Schmidt D, et al. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst. 2013;105(20):1550-1557.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;6:69-90.
Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97(14):1072-1079.
Killeen JL, Dye T, Grace C, Hiraoka M. Improved abnormal Pap smear triage using cervical cancer biomarkers. J Low Genit Tract Dis. 2014;18(1):1-7.
Lee SJ, Jung KL, Lee JW, et al. Analyses of atypical squamous cells refined by the 2001 Bethesda System: the distribution and clinical significance of follow-up management. Int J Gynecol Cancer. 2006;16(2):664-669.
Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013;17(Suppl 1):S1-S27.
Medline Plus. Pap smear. http://www.nlm.nih.gov/medlineplus/ency/article/003911.htm. Accessed January 8, 2014.
National Cancer Institute Dictionary of Cancer Terms. Atypical squamous cells of undertermined significance. http://www.cancer.gov/dictionary?CdrID=655175. Accessed January 8, 2014.
National Cancer Institute. SEER Stat fact sheets: number of new cases and deaths per 100,000 people (all races, both sexes). http://seer.cancer.gov/statfacts/html/ld/cervix.html. Accessed December 6, 2013.
NHS Cervical Screening Programme annual review 2012. http://www.cancerscreening.nhs.uk/cervical/publications/cervical-annual-review-2012.pdf. Accessed December 6, 2013.
National Health and Medical Research Council. Screening to prevent cervical cancer: Guidelines for the management of asymptomatic women with screen detected abnormalities. Commonwealth of Australia. Commonwealth of Australia; 2005.
Petry KU, Schmidt D, Scherbring S, et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 dual-stained cytology. Gynecol Oncol. 2011;121(3):505-509.
Public Health England. Statistics for the NHS Cervical Screening Programme. http://www.cancerscreening.nhs.uk/cervical/statistics.html. Accessed December 6, 2013.
Saah AJ, Hoover DR. “Sensitivity” and “specificity” reconsidered: the meaning of these terms in analytical and diagnostic settings. Ann Intern Med. 1997;126(1):91-94.
Saslow D, Solomon D, Lawson HW, et al; for the ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62:147-172.
Schmidt D, Bergeron C, Denton KJ, Ridder R; for the European CINtec Cytology Study Group. p16/Ki-67 dual-stain cytology in the triage of ASCUS and LSIL Papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathol. 2011;119(3):158-166.
Sherman ME, Castle PE, Solomon D. Cervical cytology of atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion (ASC-H): characteristics and histologic outcomes. Cancer. 2006;108(5):298-305.
Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. Journ Am Med Assoc. 2002;287(16):2114-2119.
Stoler MH, Wright Jr TC, Sharma A, Apple R, Gutekunst K; for the ATHENA HPV Study Group. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV Study. Am J Clin Pathol. 2011;135(3):468-475.
Wentzensen N, Schwartz L, Zuna RE, et al. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin Cancer Res. 2012;18(15):4154-4162.
Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer. 2007;7(1):11-22.